J Neurol Surg B Skull Base 2017; 78(02): 132-138
DOI: 10.1055/s-0036-1593469
Original Article

Role of Glioblastoma Craniotomy Related to Patient Survival: A 10-Year Survey in a Tertiary Care Hospital in Pakistan

Saman Shahid
1   Department of Sciences and Humanities, National University of Computer and Emerging Sciences (NUCES), Foundation for Advancement of Science and Technology (FAST), Lahore, Pakistan
,
Kamran Hussain
2   Department of Neurosurgery, Federal Post Graduate Medical Institute, Shaikh Zayed Hospital, Lahore, Pakistan
› Author Affiliations

Abstract

A total of 270 glioblastoma patients were treated for tumor resection during 2004 to 2014. The following variables were examined: patient age group (PAG) and percent of the extent of resection (EOR) in four types of resections: gross total resection (GTR), subtotal resection (STR), partial resection (PR), and biopsy/decompression (BD). The Karnofsky performance scale (KPS) was used and the average survival time noted. The least survival time (7 months) was noticed in the patient age group 18 to 35 years with biopsy only, whereas, the maximum survival time (14.5 months) was noted with the patient age group 54 to 71 years by gross tumor resection. The largest number of (n = 76) patients had PR (80%) and these patients had an average survival time of 10.5 months. Total 190 patients out of 270, with EOR (100–80%) had a KPS score “0” (80 and above) and total 80 patients out of 270 patients, with EOR (50%) had a KPS score “1” (below 80). The correlation was statistically significant at (p < 0.050) for EOR (%) and KPS score (0/1) only. Correlation analysis showed that the maximum resection has a strong impact on the glioblastoma patient's survival. A lesser EOR correlated with poor quality of life and also a decreased survival of patients.



Publication History

Received: 07 April 2016

Accepted: 22 August 2016

Publication Date:
10 October 2016 (online)

© 2016. Thieme. All rights reserved.

Georg Thieme Verlag KG
Stuttgart · New York

 
  • References

  • 1 Eyüpoglu IY, Buchfelder M, Savaskan NE. Surgical resection of malignant gliomas-role in optimizing patient outcome. Nat Rev Neurol 2013; 9 (03) 141-151
  • 2 Bloch O, Han SJ, Cha S. , et al. Impact of extent of resection for recurrent glioblastoma on overall survival: clinical article. J Neurosurg 2012; 117 (06) 1032-1038
  • 3 Grabowski MM, Recinos PF, Nowacki AS. , et al. Residual tumor volume versus extent of resection: predictors of survival after surgery for glioblastoma. J Neurosurg 2014; 121 (05) 1115-1123
  • 4 Hassaneen W, Levine NB, Suki D. , et al. Multiple craniotomies in the management of multifocal and multicentric glioblastoma. Clinical article. J Neurosurg 2011; 114 (03) 576-584
  • 5 Ohgaki H, Kleihues P. Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas. J Neuropathol Exp Neurol 2005; 64 (06) 479-489
  • 6 Kohler BA, Ward E, McCarthy BJ. , et al. Annual report to the nation on the status of cancer, 1975-2007, featuring tumors of the brain and other nervous system. J Natl Cancer Inst 2011; 103 (09) 714-736
  • 7 McLendon R, Friedman A, Bigner D. , et al; Cancer Genome Atlas Research Network. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 2008; 455: 1061-1068
  • 8 Sawaya R, Hammoud M, Schoppa D. , et al. Neurosurgical outcomes in a modern series of 400 craniotomies for treatment of parenchymal tumors. Neurosurgery 1998; 42 (05) 1044-1055
  • 9 American Association of Neuroscience Nurses. Guide to the care of the patients with craniotomy post-brain tumor resection. 2006. https://www.scribd.com/document/232382883/Guide-to-the-Care-of-the-Patient-With-Craniotomy-Post-Brain-Tumor-Resection . Accessed September 22, 2016
  • 10 Kuhnt D, Becker A, Ganslandt O, Bauer M, Buchfelder M, Nimsky C. Correlation of the extent of tumor volume resection and patient survival in surgery of glioblastoma multiforme with high-field intraoperative MRI guidance. Neuro-oncol 2011; 13 (12) 1339-1348
  • 11 Genc M, Zorlu AF, Atahan IL. Accelerated hyperfractionated radiotherapy in supratentorial malignant astrocytomas. Radiother Oncol 2000; 56 (02) 233-238
  • 12 McGirt MJ, Chaichana KL, Gathinji M. , et al. Independent association of extent of resection with survival in patients with malignant brain astrocytoma. J Neurosurg 2009; 110 (01) 156-162
  • 13 Chaichana KL, Jusue-Torres I, Navarro-Ramirez R. , et al. Establishing percent resection and residual volume thresholds affecting survival and recurrence for patients with newly diagnosed intracranial glioblastoma. Neuro-oncol 2014; 16 (01) 113-122
  • 14 Chaichana KL, Zadnik P, Weingart JD. , et al. Multiple resections for patients with glioblastoma: prolonging survival. J Neurosurg 2013; 118 (04) 812-820
  • 15 Hentschel SJ, Sawaya R. Optimizing outcomes with maximal surgical resection of malignant gliomas. Cancer Contr 2003; 10 (02) 109-114
  • 16 Lacroix M, Abi-Said D, Fourney DR. , et al. A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. J Neurosurg 2001; 95 (02) 190-198
  • 17 Kumar V, Abbas AK, Fausto N. , et al. Robbins and Cotran Pathologic Basis of Disease, Professional Edition: Expert Consult-Online. Philadelphia, PA: Elsevier Health Sciences; 2009
  • 18 van den Bent MJ, Dubbink HJ, Marie Y. , et al. IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor Group. Clin Cancer Res 2010; 16 (05) 1597-1604
  • 19 Stummer W, Pichlmeier U, Meinel T, Wiestler OD, Zanella F, Reulen HJ. ; ALA-Glioma Study Group. Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial. Lancet Oncol 2006; 7 (05) 392-401
  • 20 Albert FK, Forsting M, Sartor K, Adams HP, Kunze S. Early postoperative magnetic resonance imaging after resection of malignant glioma: objective evaluation of residual tumor and its influence on regrowth and prognosis. Neurosurgery 1994; 34 (01) 45-60 , discussion 60–61
  • 21 Barker II FG, Prados MD, Chang SM. , et al. Radiation response and survival time in patients with glioblastoma multiforme. J Neurosurg 1996; 84 (03) 442-448
  • 22 Vecht CJ, Avezaat CJ, van Putten WL, Eijkenboom WM, Stefanko SZ. The influence of the extent of surgery on the neurological function and survival in malignant glioma. A retrospective analysis in 243 patients. J Neurol Neurosurg Psychiatry 1990; 53 (06) 466-471
  • 23 Simpson JR, Horton J, Scott C. , et al. Influence of location and extent of surgical resection on survival of patients with glioblastoma multiforme: results of three consecutive Radiation Therapy Oncology Group (RTOG) clinical trials. Int J Radiat Oncol Biol Phys 1993; 26 (02) 239-244
  • 24 Tait MJ, Petrik V, Loosemore A, Bell BA, Papadopoulos MC. Survival of patients with glioblastoma multiforme has not improved between 1993 and 2004: analysis of 625 cases. Br J Neurosurg 2007; 21 (05) 496-500
  • 25 Chaichana KL, Garzon-Muvdi T, Parker S. , et al. Supratentorial glioblastoma multiforme: the role of surgical resection versus biopsy among older patients. Ann Surg Oncol 2011; 18 (01) 239-245